The extended analysis is outlined in the slide presentation in this post.
PharmacoEconomics recently published OHE’s study projecting medicines expenditure in the UK to 2015. The PPRS 2014 Heads of Agreement was announced on 6 November 2013, which outlines the terms of the five-year deal between the pharmaceuctical industry and the government in the UK.
PharmacoEconomics recently published OHE’s study projecting medicines expenditure in the UK to 2015[1]. The PPRS 2014 Heads of Agreement was announced on 6 November 2013, which outlines the terms of the five-year deal between the pharmaceuctical industry and the government in the UK. For the first time in the UK, the PPRS caps future growth in the NHS’s branded medicines bill, between 2014 and 2018. OHE’s model for projecting NHS medicines expenditure was an important tool used by the Association of the British Pharmaceutical Industry (ABPI) to produce its forecast for discussion with the Department of Health.
OHE extended the model published in PharmacoEconomics to cover the evolution of NHS medicines expenditure until the end of 2018. The presentation below shows the projections for this longer period, which are based on the same methodology as in the PharmacoEconomics article. We will shortly publish an OHE Occasional Paper describing these results in greater detail.
Download: UK NHS Medicines Bill Projection: Methodology and Results 2013-2018
[1]O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J. (2013) Projecting expenditure on medicines in the UK NHS. 31(10), 933-957.
This journal article is a refinement of an OHE Research Paper available on this website. O’Neill, P., Mestre-Ferrandiz, J., Puig-Peiro, R. and Sussex, J. (2013) Projecting expenditure on medicines in the NHS. Research Paper 13/02. London: Office of Health Economics.
